+ 39 011 76 51 239

info@adreshe.com

Via Vittorio Alfieri, 17

Torino (To)

Follow Us

2008

2008

  • ReadSacchi V. Maraviroc (Celsentri) in HIV treatment. Farmeconomia e percorsi terapeutici 2008; 9(4): 219-222. Edited by AdRes Health Economics & Outcomes Research
  • ReadSacchi V. Telbivudine (Sebivo) in patients with hepatitis B virus (HBV) chronic infection. Farmeconomia e percorsi terapeutici 2008; 9(4): 215-218. Edited by AdRes Health Economics & Outcomes Research
  • ReadPradelli L. Usefulness and limitation of DDD and PDD analyses. 12 months of solid oral antipsychotics prescribing data for the NHS-reimbursed treatment of schizophrenia in Italy. Farmeconomia e percorsi terapeutici 2008; 9(4): 191-196
  • ReadSacchi V. Daptomycin (Cubicin) in patients with complicated skin or soft-tissue infections. Farmeconomia e percorsi terapeutici 2008; 9(3): 163-166. Edited by AdRes Health Economics & Outcomes Research
  • ReadSacchi V. Entecavir (Baraclude) in patients with chronic hepatitis B virus (HPV) infection. Farmeconomia e percorsi terapeutici 2008; 9(3): 157-161. Edited by AdRes Health Economics & Outcomes Research
  • ReadIannazzo S, Pradelli L. Cost-efficacy analysis of hormonal treatments for advanced prostate cancer. Farmeconomia e percorsi terapeutici 2008; 9(3): 147-156
  • ReadZaniolo O, Sacchi V, Pradelli L. Budget impact of vildagliptin. Farmeconomia e percorsi terapeutici 2008; 9(3): 137-146
  • ReadIannazzo S, Pradelli L, Zaniolo O. Pharmacoeconomic analysis of valsartan for the treatment of chronic congestive heart failure in Italy. Farmeconomia e percorsi terapeutici 2008; 9(3): 125-135
  • ReadSacchi V. Rotigotine patches (Neupro) in early Parkinson’s disease. Farmeconomia e percorsi terapeutici 2008; 9(2): 115-119. Edited by AdRes Health Economics & Outcomes Research
  • ReadSacchi V. Natalizumab (Tysabri) in multiple sclerosis patients. Farmeconomia e percorsi terapeutici 2008; 9(2): 109-114. Edited by AdRes Health Economics & Outcomes Research
  • ReadZaniolo O, Iannazzo S. Sartans: differences, similitudes and costs. Farmeconomia e percorsi terapeutici 2008; 9(2): 69-88
  • ReadPradelli L. Parnaparin: review of the literature. Farmeconomia e percorsi terapeutici 2008; 9(1): 27-40
  • ReadIannazzo S, Pradelli L. Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis. Farmeconomia e percorsi terapeutici 2008; 9(1): 5-14
  • ReadIannazzo S, Zaniolo O, Pradelli L. Economic evaluation of treatment with orlistat in Italian obese patients. Curr Med Res Opin 2008; 24(1): 63-74
  • ReadPradelli L, Eandi M. Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects. Tumori 2008; 94: 26-32
  • ReadCremonesi G, Pradelli L. Profilo farmacologico, clinico ed economico dell’associazione fissa di beclometasone dipropionato e formoterolo in formulazione extra-fine nella terapia di pazienti con asma bronchiale. Profili in Farmacoeconomia 2008; 7
  • ReadZaniolo O, Pradelli L. La schizofrenia: percorsi diagnostico-terapeutici e costo di malattia. Profili in Farmacoeconomia 2008; 6
2009
2007
No Comments

Sorry, the comment form is closed at this time.